Sunita sSxena who has used the much-acclaimed Ayurvedic medicine BGR 34 released into the market by CSIR without authentic clinical trials. But after 10 days of the dosage, she complained of chronic gastric problems and severe allergy.
“BGR 34 is really not a recommended medicine, I took the dosage for nearly 10 days initially (and) I was suffering from gastric disorders and now I have a severe allergy all over my body… So I won’t recommend the tablet to anyone,” she said.
- Made from medicinal plant extracts, Aimil BGR-34 is an anti-diabetes herbal and ayurvedic drug
- Works as a blood glucose metabolizer and protects vital organs from oxidative damage
- A rich source of daruharidra, vijaysar, giloy, gudmar, methika and majeeth
- Improves the function of the pancreas and reduces the level of glycosylated hemoglobin
- Approved by the Indian ministry, this drug is jointly developed by the scientists of CSIR-NBRI and CSIR- CIMAP.
While the initial apprehensions were about the high price being charged for the tablet, being an Ayurvedic drug it has circumvented the scientific trials like allopathic medicine though CSIR, which has developed the medicine claimed that it has conducted some clinical trials on animals without revealing details to the public.
Otherwise, the craze for the ‘magic’ medicine to treat diabetes attracted immense curiosity and demand in the market as it claimed 67% success during the “clinical trials.”. Available online, the partically validated anti-diabetes herbal drug BGR-34 was launched commercially by a Council of Scientific and Industrial Research (CSIR) lab in Lucknow few months ago, assuring that it has no side effects.
Priced relatively much higher than an allopathic drug at Rs.5 per tablet, the drug manufactured by Aimil Pharmaceuticals, has been jointly developed by two CSIR laboratories, National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plant (CIMAP) — both funded by the government.
“The drug has extracts from four plants mentioned in Ayurveda and that makes it safe,” said Dr AKS Rawat, senior principal scientist, NBRI, while releasing the drug in the market. “It has been tested on animals and scientific study has found it safe and effective, with clinical trials showing 67% success,” said the scientist without giving the details.
The NBRI claims that the drug boosts immune system, works as antioxidant and checks free radicals. Compared to the allopathic medicine for diabetes called Melmet that is sold Rs.25 for 15 tablets, almost Re.1.60 per tablet, the Ayurvedic medicine at Rs.5 per tablet is almost three times higher in price though the Ayurvedic and Herbal medicines are funded by the government research.